Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs AGIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PVLA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

PVLA Overall Winner 6-Pillar Tally: PVLA 3 – 2 AGIO (1 Tie) Matrix Metrics: PVLA 5 – 5 AGIO

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Agios Pharmaceuticals, Inc. (AGIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas AGIO carries 58.1/100 (HOLD) at $30.42 (2.5x Forward P/E, -297.7% operating margin).

  • Composite vs. Pillar Nuance: While AGIO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -297.7% operating margin) and revenue trajectory (+0.0% vs. +330.0% YoY).
  • Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile AGIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs AGIO
PVLA NASDAQ Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
Pharmaceutical Preparations
$30.42
-3.7% 1D
Market Cap $1.9B
TTM Revenue $141M
Forward P/E 2.5x
Beta / 30D Vol 1.12β · 85% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 81.0 Fund 62.0 Flow 50.0 Mom 53.3
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 44
RSI-14: 44.4 · SMA20: $33.46 · SMA50: $33.04

6-Pillar Scorecard Institutional Category Breakdown (PVLA 3 – 2 AGIO)

Columns: Metric · PVLA · AGIO
1. Valuation Multiples AGIO
Forward P/E N/M 2.5x
Trailing P/E N/M 2.5x
PEG Ratio N/M N/M
EV / Revenue N/M 13.5x
2. Growth & Scale AGIO
Revenue Growth (YoY) +0.0% +330.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $141M
Market Cap $2.2B $1.9B
3. Profitability & Quality PVLA
Gross Margin N/A N/A
Operating Margin 0.0% -297.7%
Net Profit Margin 0.0% -264.8%
Return on Equity (ROE) -63.4% -33.0%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$43M -$414M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $193M Net Cash $16.38 Book/Sh · -33.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PVLA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 47.9% (2nd %ile) 65.7% (16th %ile)
Put/Call OI Skew 3.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (5) vs AGIO (5)
Institutional Metric PVLA AGIO Criterion Row Edge
Market Capitalization
Scale
$2.2B $1.9B Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M 2.5x Lower Multiple AGIO
Forward P/E Ratio
Valuation
N/M 2.5x Lower Multiple AGIO
Revenue Growth (YoY)
Growth
+0.0% +330.0% Higher Growth AGIO
Operating Margin (TTM)
Profitability
0.0% -297.7% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% -264.8% Higher Margin PVLA
Return on Equity (ROE)
Capital Efficiency
-63.4% -33.0% Higher ROE AGIO
52-Week Range Position
Momentum
68% ($72–$180) 34% ($22–$46) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.12β · 85% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite AGIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $141M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 13.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$414M EBITDA ($16.38 Book/Sh · -33.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +23.43 pp
PVLA: +20.56% · AGIO: -2.87%
3M Horizon PVLA +7.99 pp
PVLA: -3.58% · AGIO: -11.57%
6M Horizon PVLA +30.23 pp
PVLA: +38.06% · AGIO: +7.83%
1Y Horizon PVLA +108.65 pp
PVLA: +80.16% · AGIO: -28.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs AGIO. Trailing 12-month operating profitability (PVLA 0.0% vs AGIO -297.7%) and valuation multiples (PVLA N/M vs AGIO 2.5x Forward P/E) are benchmarked directly in Pillar 4 below.

PVLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.4% · N/M
AGIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$141M
Gross MarginN/A
Op. Margin-297.7%
ROE / Fwd P/E-33.0% · 2.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AGIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.7%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AGIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AGIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -297.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs AGIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Agios Pharmaceuticals, Inc. (AGIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas AGIO carries 58.1/100 (HOLD) at $30.42 (2.5x Forward P/E, -297.7% operating margin). Composite vs. Pillar Nuance: While AGIO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -297.7% operating margin) and revenue trajectory (+0.0% vs. +330.0% YoY). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile AGIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGIO leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AGIO at +330.0% YoY revenue growth and +0.0% YoY earnings growth on $141M TTM revenue (N/A gross margin, -297.7% operating margin). On trailing 12-month operating scale, PVLA generates N/A in USD-normalized revenue versus $141M for AGIO. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGIO.

AGIO screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AGIO trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 13.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus AGIO (-33.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, AGIO carries 65.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.